Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ming Hong
Institution:
Zhongshan People's Hospital
Observed institution:
Zhongshan People's Hospital
ORCID:
0000-0003-0420-6631
Observed ORCID:
0000-0003-0420-6631
OpenAlex ID:
A5124255364
BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial
2026
·
Ming Hong
, Mingxia Wang
, et al.
·
Journal of Hematology & Oncology
·
22
PDF
Dual‐Targeting BCMA – CD19 CAR ‐T Cell Therapy in Systemic Lupus Erythematosus: Single‐Cell and Immune Repertoire Analysis Reveals Mechanisms of Immune Reconstitution
2026
·
Zhenghao He
, Weijia Wang
, et al.
·
Arthritis & Rheumatology
·
9
Successful Spontaneous Pregnancies and Healthy Neonates After Dual‐Target CAR –T Cell Therapy in Systemic Lupus Erythematosus
2026
·
Qinglian Jiang
, Mingxia Wang
, et al.
·
Arthritis & Rheumatology
·
3
PDF
PT4:02 Landmark long-term remission achieved with ICG318, a BCMA-CD19 armored compound CAR T-cell therapy, in refractory systemic lupus erythematosus/lupus nephritis with follow-up approaching 6 years
2026
·
Ming Hong
, Mingxia Wang
, et al.
·
Lupus Science & Medicine
·
1
PDF
Landmark Long-Term Remission Achieved with ICG318, a BCMA-CD19 Armored Compound CAR T-cell Therapy, in Refractory Systemic Lupus Erythematosus/Lupus Nephritis with Follow-up Approaching 6 Years
2026
·
Ming Hong
, Mingxia Wang
, et al.
·
Transplantation and Cellular Therapy
·
1
Show more works
View as search
Works count:
5
Citation count:
36
H-index:
3
I10-index:
1
Year
Topic
Type